Epidemiology of Plantar Verrucae in HIV-Infected Individuals

Kenyon, Erik; Loveland, Lacey; Kilpatrick, Richmond; Barbosa, Peter

doi:10.1097/00042560-199801010-00016

Cited by 11 publications

(3 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most HPV infections and associated lesions eventually regress due to a cell-mediated immune response [4]. However, in immunosuppressed patients including HIV positive and organ transplant recipients (OTR), warts are more numerous, tend to persist, are more difficult to treat and prevalence increases with time of immunosuppression [5–7]. …”

Section: Introductionmentioning

confidence: 99%

Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV)

et al. 2017

View full text Add to dashboard Cite

Common cutaneous human papillomavirus (HPV) types induce skin warts, whereas species beta HPV are implicated, together with UV-radiation, in the development of non-melanoma skin cancer (NMSC) in immunosuppressed patients. Licensed HPV vaccines contain virus-like particles (VLP) self-assembled from L1 major capsid proteins that provide type-restricted protection against mucosal HPV infections causing cervical and other ano-genital and oro-pharyngeal carcinomas and warts (condylomas), but do not target heterologous HPV. Experimental papillomavirus vaccines have been designed based on L2 minor capsid proteins that contain type-common neutralization epitopes, to broaden protection to heterologous mucosal and cutaneous HPV types. Repetitive display of the HPV16 L2 cross-neutralization epitope RG1 (amino acids (aa) 17–36) on the surface of HPV16 L1 VLP has greatly enhanced immunogenicity of the L2 peptide. To more directly target cutaneous HPV, L1 fusion proteins were designed that incorporate the RG1 homolog of beta HPV17, the beta HPV5 L2 peptide aa53-72, or the common cutaneous HPV4 RG1 homolog, inserted into DE surface loops of HPV1, 5, 16 or 18 L1 VLP scaffolds. Baculovirus expressed chimeric proteins self-assembled into VLP and VLP-raised NZW rabbit immune sera were evaluated by ELISA and L1- and L2-based pseudovirion (PsV) neutralizing assays, including 12 novel beta PsV types. Chimeric VLP displaying the HPV17 RG1 epitope, but not the HPV5L2 aa53-72 epitope, induced cross-neutralizing humoral immune responses to beta HPV. In vivo cross-protection was evaluated by passive serum transfer in a murine PsV challenge model. Immune sera to HPV16L1-17RG1 VLP (cross-) protected against beta HPV5/20/24/38/96/16 (but not type 76), while antisera to HPV5L1-17RG1 VLP cross-protected against HPV20/24/96 only, and sera to HPV1L1-4RG1 VLP cross-protected against HPV4 challenge. In conclusion, RG1-based VLP are promising next generation vaccine candidates to target cutaneous HPV infections.

show abstract

Section: Introductionmentioning

confidence: 99%

Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV)

et al. 2017

View full text Add to dashboard Cite

show abstract

“…HIV patients present with increased frequency and severity of common skin warts, including verrucae vulgaris and verrucae plantaris [41,42]. The prevalence of common warts in HIV-positive patients is 17% to 18%, compared with only 1% to 2% in the HIV-negative population [42].…”

Section: Common Wartsmentioning

confidence: 99%

“…The prevalence of common warts in HIV-positive patients is 17% to 18%, compared with only 1% to 2% in the HIV-negative population [42]. Verrucae plantaris in HIV patients are often larger, more numerous, more aggressive, and more recalcitrant to therapy than those verrucae presenting in HIV-negative individuals [41][42][43].…”

Section: Common Wartsmentioning

confidence: 99%

Dermatologic manifestations of HPV in HIV-infected individuals

Gormley¹,

Kovarik

2009

Curr HIV/AIDS Rep

View full text Add to dashboard Cite

Dermatologic human papillomavirus (HPV) infection in HIV patients manifests as both anogenital and nongenital skin disease. Anogenital HPV-related disease includes benign condyloma acuminata, the most common cutaneous manifestation of genital HPV infection; intermediate malignancy or premalignant conditions including giant condyloma acuminata (also called Buschke-Loewenstein tumor), anal intraepithelial neoplasia, penile intraepithelial neoplasia, and vaginal or vulvar intraepithelial neoplasia; and frankly malignant disease including Bowen's disease and invasive anal, penile, or vulvar carcinoma. Cutaneous HPV-related disease in nongenital skin is also increased in HIV-positive patients, in the form of benign common warts, epidermodysplasia verruciformis-like skin lesions, and nonmelanoma skin cancers. This review and update addresses the above listed dermatologic manifestations of HPV disease in HIV-infected individuals, with an emphasis on new findings and published data from 2006 to 2008.

show abstract